Friday, 27 September 2013

Uzbekistan Pharmaceuticals and Healthcare Report Q4 2013

Business Monitor International Market Research Reports
Market Reports Online XML Feed 
300+% Conversion Increase

Learn how startups and leading businesses alike are getting huge results using web personalization and behavioral targeting the easy way in this ebook. Get it now!
From our sponsors
Uzbekistan Pharmaceuticals and Healthcare Report Q4 2013
Sep 25th 2013, 00:00

Price: $ 1295  

BMI View: As the most populous state in Central Asia, with a population expected to increase to 29.8mn by 2017, we expect interest in the pharmaceutical and healthcare markets to increase. However, Uzbekistan has a number of obstacles to overcome before it will present an attractive prospect to potential investors. For one thing, the country ranks as the least attractive in BMI's ratings matrix, with high corruption, a repressive political regime and deficient intellectual property rights (IPRs) enforcement. Furthermore, the tightening up on medicine imports in December 2012, and the state's control of pharmaceutical production and procurement, means there little room for drugmakers to enter the market in our short-term view. It has also led us to downgrade out forecast for the Uzbek pharmaceutica ...

Complete report details with Table of Contents and more @

Delicious Digg Evernote Facebook Google Bookmarks Google Plus LinkedIn StumbleUpon Tumblr Twitter
You are receiving this email because you subscribed to this feed at

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

No comments:

Post a Comment